Analysts expect The Medicines Company (NASDAQ:MDCO) to post earnings of ($0.65) per share for the current quarter, Zacks reports. Two analysts have issued estimates for The Medicines’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.68). The Medicines posted earnings of ($0.63) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 3.2%. The company is expected to announce its next earnings report on Wednesday, August 7th.
On average, analysts expect that The Medicines will report full year earnings of ($2.31) per share for the current fiscal year, with EPS estimates ranging from ($2.47) to ($2.02). For the next year, analysts forecast that the business will post earnings of ($2.22) per share, with EPS estimates ranging from ($2.37) to ($2.13). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for The Medicines.
The Medicines (NASDAQ:MDCO) last released its earnings results on Thursday, April 25th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.71) by ($0.09). The firm’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.76) EPS.
The Medicines stock traded up $0.61 during mid-day trading on Friday, reaching $31.89. 870,730 shares of the company’s stock were exchanged, compared to its average volume of 1,096,590. The firm has a market cap of $2.36 billion, a PE ratio of -10.96 and a beta of 1.36. The Medicines has a twelve month low of $16.69 and a twelve month high of $41.57.
In related news, Director Alexander J. Denner bought 325,000 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The shares were purchased at an average cost of $25.45 per share, with a total value of $8,271,250.00. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Alexander J. Denner bought 100,000 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was bought at an average cost of $25.15 per share, for a total transaction of $2,515,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 673,100 shares of company stock worth $16,966,421 over the last 90 days. Company insiders own 10.29% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of MDCO. MetLife Investment Advisors LLC grew its position in shares of The Medicines by 55.0% in the 3rd quarter. MetLife Investment Advisors LLC now owns 49,654 shares of the company’s stock valued at $1,485,000 after buying an additional 17,616 shares during the last quarter. Teachers Advisors LLC grew its position in shares of The Medicines by 1.2% in the 3rd quarter. Teachers Advisors LLC now owns 257,633 shares of the company’s stock valued at $7,706,000 after buying an additional 3,164 shares during the last quarter. Legal & General Group Plc grew its position in shares of The Medicines by 8.9% in the 3rd quarter. Legal & General Group Plc now owns 154,079 shares of the company’s stock valued at $4,598,000 after buying an additional 12,563 shares during the last quarter. Vanguard Group Inc. grew its position in shares of The Medicines by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 6,681,573 shares of the company’s stock valued at $199,846,000 after buying an additional 162,702 shares during the last quarter. Finally, Federated Investors Inc. PA purchased a new position in shares of The Medicines in the 3rd quarter valued at $6,275,000.
The Medicines Company Profile
The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.
Featured Article: NASDAQ
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.